ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BHVN / news
PBH (62) PHVS (59) RCUS (19) HCM (34) ⌘ Pro Terminal →

Why BHVN Stock slipped -1.69% Today — RQD Quant Desk Flash

$15.16 -1.69% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.09

Biohaven Ltd. (BHVN) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BHVN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BHVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Biohaven Ltd. (NYSE: BHVN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $15.16 (-1.69% 1D, market cap $2.33B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BHVN ranks #381 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BHVN compare to PBH and PHVS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHVN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBH (Prestige Consumer Healthcare Inc.) holds a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B) and PHVS (Pharvaris N.V.) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BHVN?
▼

Per BHVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001935979), Biohaven Ltd. generated $2.09B in revenue (-15.8% YoY), -$738.8M in net income, and -$610.2M in free cash flow against $451.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.09 (-0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (6)Whales (16)SEC (10)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$19 Bull$14 Base$11 Bear
📬 FREE BHVN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BHVN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY BHVN SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$11.42+3.4% Next Q
Q2 (-2Q)
39
Grade E$11.81+29.5% Next Q
Q3 (-1Q)
41
Grade D$15.29-0.9% Next Q
Current
44
Grade D$15.16-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BHVN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BHVN currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.71) and Max Pain ($15.92) forces dealer call-delta covering toward $19.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BHVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BHVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BHVN Stock slipped -1.69% Today — RQD Quant Desk Flash

Biohaven Ltd. (BHVN) slipped -1.69% to $15.16, trading at 71% of its 52-week range ($7.48 – $18.24). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 71% of its 52-week range ($7.48 – $18.24) with RSI-14 at 58.4 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.16 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BHVN Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BHVN)

  • ✓Walkthrough of BHVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BHVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +49.51%📐 HORIZONTAL RANGE
2026-11-03O $16.49H $16.49L $15.16C $15.16VOL 3.16M
RES: $19.60SUP: $10.15SMA50: $13.71SMA200: $12.26
$18.94$16.04$13.13$10.22$7.32RES $19.60SUP $10.15$15.162026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BHVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BHVN Butterfly Map → + Track BHVN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -15.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BHVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BHVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BHVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BHVN)

Health Care Rank #381 of 1015 ⚔️ PBH vs BHVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BHVN vs. PBH, PHVS, RCUS, HCM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Biohaven Ltd. (BHVN) ranks #381 by composite RQD confidence (44/100, grade D) and #229 by equity capitalization ($2.33B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BHVN at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BHVN ACTIVE
Biohaven Ltd.
D 44/100 — — -35.0% -1.69% $2.33B Benchmark Subject
PBH
Prestige Consumer Healthcare Inc.
C 62/100 12.1x 54.7% 13.8% +1.37% $2.32B /pbh-vs-bhvn →
PHVS
Pharvaris N.V.
C- 59/100 — — — 0.00% $2.34B /phvs-vs-bhvn →
RCUS
Arcus Biosciences Inc.
E 19/100 — — -35.0% -1.87% $2.32B /rcus-vs-bhvn →
HCM
HUTCHMED (China) Limited
E 34/100 5.2x — -2.5% +0.91% $2.29B /hcm-vs-bhvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001935979 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biohaven Ltd. (BHVN) reported GAAP revenue of $2.09B (-15.8% vs. FY2024 revenue of $2.48B , and +70.9% cumulative change since FY2023) , GAAP net income of -$738.8M, operating cash flow of -$609.4M, and free cash flow of -$610.2M (-4.0% YoY). On the balance sheet, BHVN closed FY2025 with $451.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.09B -$738.8M -$609.4M -$610.2M $451.4M —
FY2024 (FY) 2024-12-31 $2.48B -$846.4M -$582.5M -$586.5M $615.1M —
FY2023 (FY) 2023-12-31 $1.22B -$408.2M -$331.7M -$331.7M — —

3. BHVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BHVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Biohaven Ltd. (NYSE: BHVN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $15.16 (-1.69% 1D, market cap $2.33B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BHVN ranks #381 in composite RQD confidence.

How does BHVN compare to PBH and PHVS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHVN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBH (Prestige Consumer Healthcare Inc.) holds a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B) and PHVS (Pharvaris N.V.) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BHVN?

Per BHVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001935979), Biohaven Ltd. generated $2.09B in revenue (-15.8% YoY), -$738.8M in net income, and -$610.2M in free cash flow against $451.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BHVN trading relative to its 50-day, 200-day, and 52-week technical levels?

BHVN last traded at $15.16 (-1.69% on volume of 2,592,336 shares), positioning the stock +10.58% above its 50-day simple moving average ($13.71) and +23.65% above its 200-day simple moving average ($12.26). Across its 52-week range of $7.48 to $18.24, BHVN sits at the 71.4% percentile with a 14-day RSI of 58.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($13.26 to $17.06).

Direct Sub-Reports: BHVN RQD Cockpit BHVN 12M Forecast BHVN Earnings & Move BHVN Dividends & DRIP BHVN Insiders & 13F BHVN Whale Options BHVN Profit Sankey BHVN News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

BHVN — Biohaven Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Biohaven Ltd. (BHVN) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $15.16 (-1.69% 1D, market capitalization $2.33B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -24.50%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Biohaven Ltd. (BHVN) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The FY 2025, FY 2024, and FY 2023 financials each report revenue of —, indicating no reported revenue in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Biohaven Ltd. (BHVN) reported $2.09B in annual revenue (up from $2.48B in FY2024, -15.8% YoY) and -$738.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.22B revenue, -$408.2M net income) through FY2025, BHVN scaled operating cash flow to -$609.4M and free cash flow to -$610.2M, backed by $451.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -24.50% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $7.48 – $18.24 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order links are recorded. — for supplier, customer, or competitor relationships. The sector and industry classifications are provided, but no mapping of ripple effects is available in the source. A prospective investor should note that the catalyst-driven price moves in the news feed are not linked to any specific supply-chain dependency in the source data.

  • Key Question #1: Can BHVN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.09B and free cash flow of -$610.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BHVN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BHVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Biohaven Ltd. (BHVN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BHVN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BHVN Bull vs. Bear Conversation Board — What's Your Call at $15.16?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BHVN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BHVN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $19.58 (+27.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 17/20, and recent news reports a roughly 25% surge tied to an FDA resubmission

Institutional accumulation and options positioning score 17/20, and recent news reports a roughly 25% surge tied to an FDA resubmission acceptance and a deal with payments of up to $100 million.. When you look under the hood at BHVN, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $18.24. My 12M target is $19.58.

VolSurface_Trader 🐂 BULL

Both sides have a point here — BHVN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $12.49 (-19.0%)
Spot @ $15.42

ROIC of -35%, FCF of -$610.2M in FY 2025, and an insider conviction score of 3/20 indicate the business is consuming cash without reven

Here is the bear case nobody on the bull side wants to address on BHVN: ROIC of -35%, FCF of -$610.2M in FY 2025, and an insider conviction score of 3/20 indicate the business is consuming cash without revenue and without insider support.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE